Hydrogen sulfide: Recent development of its dual donors and hybrid drugs
British Journal of Pharmacology · 2026-01 · 183 (1) · 70-82
DOI: 10.1111/bph.16211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, 2023-09. Verfasst von Shi Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Brown University, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Hydrogen Sulfide. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Hydrogen sulfide (H 2 S) is an important gaseous signalling molecule known to be critically involved in regulating cellular redox homeostasis. As the beneficial and therapeutic effects of H 2 S in pathophysiology, such as in cardiovascular and neurodegenerative diseases, have emerged, so too has the drive for the development of H 2 S‐releasing compounds (aka donors) and their therapeutic applications. Most reported donor compounds singularly release H 2 S through biocompatible triggers. An emerging area in the field is the development of compounds that can co‐deliver H 2 S with other drugs or biologically relevant species, such as reactive oxygen and nitrogen species (ROS and RNS, respectively). These H 2 S‐based dual donors and hybrid drugs are expected to offset negative side effects from individual treatments or achieve synergistic effects rendering them more clinically effective. Additionally, considering that molecules exist and interact physiologically, dual donors may more accurately mimic biological systems as compared to single donors and allow for the elucidation of fundamental chemistry and biology. This review focuses on the recent advances in the development of H 2 S‐based dual donors and hybrid drugs along with their design principles and synergistic effects. LINKED ARTICLES This article is part of a themed issue Recent Innovations in Targeting Redox Biology for Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.1/issuetoc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Brown University, Providence, Rhode Island, USA.
- Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Lieber Institute for Brain Development, Baltimore, Maryland, USA.
ORCID-Profile: Meg Shieh, Bindu D Paul
Förderung
- NIA NIH HHS
- NIH HHS
- NHLBI NIH HHS
- NIGMS NIH HHS
- NIDA NIH HHS
- American Heart Association and Paul Allen Foundation Grant
- National Institutes of Health
Zitieren
APA
Xu, S., Shieh, M., Paul, B. D., & Xian, M. (2026). Hydrogen sulfide: Recent development of its dual donors and hybrid drugs. British Journal of Pharmacology, 183(1), 70-82. https://doi.org/10.1111/bph.16211
Vancouver
Xu S, Shieh M, Paul BD, Xian M. Hydrogen sulfide: Recent development of its dual donors and hybrid drugs. British Journal of Pharmacology. 2026;183(1):70-82. doi:10.1111/bph.16211
BibTeX
@article{Xu2026,
author = {Xu, Shi and Shieh, Meg and Paul, Bindu D and Xian, Ming},
title = {Hydrogen sulfide: Recent development of its dual donors and hybrid drugs},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {1},
pages = {70--82},
doi = {10.1111/bph.16211}
}
EUVIMED